Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).

被引：0
|
作者：
Wolchok, Jedd D.
Chiarion-Sileni, Vanna
Gonzalez, Rene
Rutkowski, Piotr
Grob, Jean Jacques
Cowey, Charles Lance
Lao, Christopher D.
Schadendorf, Dirk
Ferrucci, Pier Francesco
Smylie, Michael
Dummer, Reinhard
Hill, Andrew Graham
Haanen, John B. A. G.
Maio, Michele
McArthur, Grant A.
Yang, Arvin
Rollin, Linda
Horak, Christine E.
Larkin, James M. G.
Hodi, F. Stephen
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Oncol Inst Veneto IRCCS, Padua, Italy
[4] Univ Colorado, Ctr Canc, Denver, CO 80262 USA
[5] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland
[6] Inst Oncol, Warsaw, Poland
[7] Hosp Timone, Marseille, France
[8] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[9] Univ Michigan, Ann Arbor, MI 48109 USA
[10] Univ Essen Gesamthsch, Dept Dermatol, Essen, Germany
[11] European Inst Oncol, Milan, Italy
[12] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[13] Univ Spital Zurich, Zurich, Switzerland
[14] Tasman Oncol Res, Southport, Qld, Australia
[15] Netherlands Canc Inst, Amsterdam, Netherlands
[16] Univ Hosp Siena, Siena, Italy
[17] Peter MacCallum Canc Ctr, East Melbourne, Australia
[18] Bristol Myers Squibb Co, Princeton, NJ USA
[19] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[20] Royal Marsden Hosp, London SW3 6JJ, England
[21] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA1
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067)
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean Jacques
    Cowey, Charles Lance
    Lao, Christopher D.
    Schadendorf, Dirk
    Ferrucci, Pier Francesco
    Smylie, Michael
    Dummer, Reinhard
    Hill, Andrew Graham
    Haanen, John B. A. G.
    Maio, Michele
    McArthur, Grant A.
    Yang, Arvin
    Rollin, Linda
    Horak, Christine E.
    Larkin, James M. G.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)
  • [2] EFFICACY AND SAFETY IN KEY PATIENT SUBGROUPS OF NIVOLUMAB (NIVO) ALONE OR COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI ALONE IN TREATMENT-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) (CHECKMATE 067)
    Larkin, James
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Grob, Jean-Jacques
    Cowey, C. Lance
    Lao, Christopher D.
    Wagstaff, John
    Hogg, David
    Hill, Andrew
    Carlino, Matteo S.
    Wolter, Pascal
    Lebbe, Celeste
    Schachter, Jacob
    Thomas, Luc
    Hassal, Jessica C.
    Lorigan, Paul
    Walker, Dana
    Jiang, Joel
    Hodi, F. Stephen
    Wolchok, Jedd D.
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 126 - 126
  • [3] Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (MEL) (CheckMate 067)
    Larkin, J.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Grob, J. J.
    Cowey, C. L.
    Lao, C. D.
    Wagstaff, J.
    Hogg, D.
    Hill, A.
    Carlino, M. S.
    Wolter, P.
    Lebbe, C.
    Schachter, J.
    Thomas, L.
    Hassel, J. C.
    Lorigan, P.
    Walker, D.
    Jiang, J.
    Hodi, F. S.
    Wolchok, J. D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S664 - S665
  • [4] Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (MEL) (CheckMate 067)
    Larkin, J.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Grob, J. -J.
    Cowey, C. L.
    Lao, C. D.
    Wagstaff, J.
    Hogg, D.
    Hill, A.
    Carlino, M. S.
    Wolter, P.
    Lebbe, C.
    Schachter, J.
    Thomas, L.
    Hassel, J. C.
    Lorigan, P.
    Walker, D.
    Jiang, J.
    Hodi, F. S.
    Wolchok, J. D.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 40 - 40
  • [5] Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean Jacques
    Cowey, C. Lance
    Lao, Christopher
    Schadendorf, Dirk
    Ferrucci, Pier Francesco
    Smylie, Michael
    Dummer, Reinhard
    Hill, Andrew
    Haanen, John B. A. G.
    Maio, Michele
    McArthur, Grant A.
    Walker, Dana
    Jiang, Joel
    Horak, Christine E.
    Larkin, James M. G.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] UPDATED RESULTS FROM A PHASE 3 TRIAL OF NIVOLUMAB (NIVO) COMBINED WITH IPILIMUMAB (IPI) IN TREATMENT-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) (CheckMate 067)
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean-Jacques
    Cowey, C. Lance
    Lao, Christopher D.
    Schadendorf, Dirk
    Ferrucci, Pier F.
    Smylie, Michael
    Dummer, Reinhard
    Hill, Andrew
    Haanen, John
    Maio, Michele
    McArthur, Grant
    Walker, Dana
    Jiang, Joel
    Horak, Christine
    Larkin, James
    Hodi, Stephen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 127 - 128
  • [7] Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients with advanced melanoma (CheckMate 067)
    Larkin, James
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean-Jacques
    Cowey, C. Lance
    Lao, Christopher D.
    Schadendorf, Dirk
    Ferrucci, Pier Francesco
    Smylie, Michael
    Dummer, Reinhard
    Hill, Andrew
    Haanen, John
    Maio, Michele
    McArthur, Grant
    Walker, Dana
    Rollin, Linda
    Horak, Christine
    Hodi, F. Stephen
    Wolchok, Jedd D.
    CANCER RESEARCH, 2017, 77
  • [8] Effect of nivolumab (NIVO) in combination with ipilimumab (IPI) versus IPI alone on quality of life (QoL) in patients (pts) with treatment-naive advanced melanoma (MEL): Results of a phase II study (CheckMate 069)
    Abernethy, Amy Pickar
    Postow, Michael Andrew
    Chesney, Jason Alan
    Grossmann, Kenneth F.
    Taylor, Fiona
    Coon, Cheryl
    Gilloteau, Isabelle
    Dastani, Homa
    Gagnier, Paul
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] CHECKMATE 067: A PHASE III RANDOMIZED DOUBLE-BLIND STUDY OF NIVOLUMAB (NIVO) MONOTHERAPY OR NIVO COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI MONOTHERAPY IN PREVIOUSLY UNTREATED PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL)
    Wolchok, J. D.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Rutkowski, P.
    Grob, J. J.
    Cowey, C. L.
    Lao, C. D.
    Schadendorf, D.
    Ferrucci, P. F.
    Smylie, M.
    Dummer, R.
    Hill, A.
    Haanen, J.
    Maio, M.
    McArthur, G.
    Yang, A.
    Rollin, L.
    Horak, C.
    Larkin, J.
    Hodi, F. S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 68 - 68
  • [10] CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy in previously untreated patients (pts) with advanced melanoma (MEL)
    Wolchok, J. D.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Rutkowski, P.
    Grob, J.
    Cowey, C. L.
    Lao, C. D.
    Schadendorf, D.
    Ferrucci, P. F.
    Smylie, M.
    Dummer, R.
    Hill, A.
    Haanen, J.
    Maio, M.
    McArthur, G.
    Yang, A.
    Rollin, L.
    Horak, C.
    Larkin, J.
    Hodi, F. S.
    ANNALS OF ONCOLOGY, 2015, 26 : 28 - 28
12345